Scotland gets new option to treat blood clots

The Scottish Medicines Consortium has announced that edoxaban (Lixiana) will be available to Scottish patients to treat venous thromboembolism (VTE), which covers both pulmonary embolism (PE) and deep vein thrombosis (DVT). Edoxaban is a Non-VKA Oral Anti-Coagulants (NOACs) used to treat non-valvular atrial fibrillation (NVAF). It is used as an alternative to warfarin, which has been widely used for over 50 years but requires frequent monitoring to ensure it is working properly. Warfarin is also associated with many food and drug interactions.  Professor John McMurray, Professor of Cardiology at Glasgow University, who has researched AF in Scotland, said edoxaban gave doctors the ability to better tailor